Genentech says the U.S. Patent Office has rejected a patent covering the way it uses recombinant DNA technology to make antibodies. The biotech giant says it uses the 415 patent in making a number of therapies, has licensing agreements on the technology covered in the patent and earns royalties on claims to the patent. The Patent Office's decision came after Genentech asked it to reexamine the issue after patent officials originally rejected 36 patent claims. Genentech says it may appeal.
- see this release [1]
- check out the AP story [2]
Related Articles:
Patent ruling threatens $300M in Genentech revenue. Report [3]
MAbs are hottest segment of biotech industry. Report [4]
Standards on biotech patents get tougher. Report [5]
Links:
[1] http://www.fiercebiotech.com/press-releases/genentech-receives-notification-rejection-cabilly-patent-claims-reexamination-process
[2] http://www.forbes.com/feeds/ap/2008/02/26/ap4697242.html
[3] http://www.fiercebiotech.com/story/patent-ruling-threatens-300m-in-genentech-revenue/2005-09-29
[4] http://www.fiercebiotech.com/story/mabs-are-hottest-segment-biotech-industry/2007-10-12
[5] http://www.fiercebiotech.com/story/standards-on-biotech-patents-get-tougher/2006-09-26